● neutral
Impact
PhaseNot applicable (dietary supplement, not a drug)
Time to marketAlready in production and available as a dietary supplement in the U.S. Commercial launch in the UAE and Gulf Cooperation Council markets is pending local product registration, with timing uncertain.
A-SUQAR partially hydrolyzed guar gum (PHGG) formulation Updated Nov 7
What to watch
Watch for news on UAE product registration and initial commercial launch by Khoury Medical, which would be the first real revenue test for A-SUQAR. Also monitor Bioxytran's financing activities and the ProLectin-M registrational trial (planned 408-patient study), as the company's going-concern status makes its ability to fund operations the dominant risk.
Bull case
- A-SUQAR received a government-issued Free Sale Certificate on November 4, 2026, legalized for use in the UAE, opening a path to a region where roughly 7.5 million adults have diabetes (UAE, Saudi Arabia, Kuwait).
- A commercial distribution agreement with Khoury Medical LTD was signed in February 2026, providing a route-to-market without heavy upfront capital spending by Bioxytran.
- The product is already in production and can generate early revenue for a company that reported only $177,795 in trailing twelve-month revenue as of June 2026.
Bear case
- A-SUQAR is a dietary supplement, not an FDA-approved drug. The FDA does not evaluate or approve supplement structure/function claims before marketing, so there is no regulatory barrier protecting the product from competitors.
- Bioxytran is a pre-revenue clinical-stage biotech with an auditor going-concern warning (Fruci & Associates II, PLLC, April 2026 10-K) and negative working capital, raising questions about its ability to fund commercialization.
- The stock trades at $0.023 on the OTCQB with minimal volume (20,000 shares on Nov 5), no tracked institutional holders, and no analyst coverage, indicating very limited investor interest.